The anti-PD-1 immunotherapy was considered as a potential way to improve clinical outcomes of T-cell lymphoma and multiple myeloma cases because PD-L1 was shown to be highly expressed in tumor cells of these patients [85, 86]. Here, PDCD1 is linked to neoplasm.